CMS Updates on Medicare Drug Price Negotiation and 340B Rebate Litigation

The Centers for Medicare & Medicaid Services (CMS) announced changes to the Medicare drug price negotiation program, indicating that three of the ten drugs selected for price negotiations in 2026 will lose their negotiated status starting January 1, 2027. This adjustment follows CMS's determination that generic or biosimilar versions of these drugs are being bona fide marketed, impacting future pricing and reimbursement in Medicare Advantage and Prescription Drug Plans. Concurrently, litigation concerning the 340B drug rebate program remains active at various judicial levels. Manufacturers continue to challenge the rebate model at the appellate stage, while hospital groups have initiated separate legal action to prevent the Health Resources & Services Administration (HRSA) from implementing it. HRSA has engaged stakeholders through webinars to discuss the rebate model and posted recorded sessions to clarify its position. A private analytics firm's recent study suggests that concerns by covered entities over potential interest costs arising from the rebate system may be overstated, finding such costs to be minimal even under conservative assumptions. In addition to federal-level challenges, litigation persists against state-level 340B laws enacted by several states, highlighting the ongoing complexity and regulatory scrutiny in this area. On the Medicare Part D front, the Inflation Reduction Act (IRA) has significantly altered the financial dynamics among CMS, plans, beneficiaries, and drug manufacturers, with CMS recently completing a higher-than-usual reconciliation payment to plans for 2024. Price cap legislation at the state level, such as ongoing litigation in Connecticut, further exemplifies the evolving regulatory environment that stakeholders must navigate. These developments underscore the intricate balance of drug pricing policy, regulatory compliance, and legal challenges that continue to shape the U.S. pharmaceutical and insurance markets.